JP7126454B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP7126454B2
JP7126454B2 JP2018559221A JP2018559221A JP7126454B2 JP 7126454 B2 JP7126454 B2 JP 7126454B2 JP 2018559221 A JP2018559221 A JP 2018559221A JP 2018559221 A JP2018559221 A JP 2018559221A JP 7126454 B2 JP7126454 B2 JP 7126454B2
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutical composition
antigen
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018559221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514998A5 (enExample
JP2019514998A (ja
Inventor
ジェフリー イェーツ、アンドリュー
イーヴォ マッサン、ヤン
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56320265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7126454(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2019514998A publication Critical patent/JP2019514998A/ja
Publication of JP2019514998A5 publication Critical patent/JP2019514998A5/ja
Application granted granted Critical
Publication of JP7126454B2 publication Critical patent/JP7126454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2018559221A 2016-05-12 2017-05-11 医薬組成物 Active JP7126454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608323.0A GB201608323D0 (en) 2016-05-12 2016-05-12 Pharmaceutical compositions
GB1608323.0 2016-05-12
PCT/EP2017/061261 WO2017194646A1 (en) 2016-05-12 2017-05-11 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2019514998A JP2019514998A (ja) 2019-06-06
JP2019514998A5 JP2019514998A5 (enExample) 2020-05-21
JP7126454B2 true JP7126454B2 (ja) 2022-08-26

Family

ID=56320265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559221A Active JP7126454B2 (ja) 2016-05-12 2017-05-11 医薬組成物

Country Status (18)

Country Link
US (1) US11407835B2 (enExample)
EP (1) EP3454899B1 (enExample)
JP (1) JP7126454B2 (enExample)
KR (1) KR102436694B1 (enExample)
CN (1) CN109069643A (enExample)
AR (1) AR108449A1 (enExample)
AU (1) AU2017264553A1 (enExample)
BR (1) BR112018072264A2 (enExample)
CA (1) CA3022124A1 (enExample)
CL (1) CL2018003178A1 (enExample)
CO (1) CO2018011733A2 (enExample)
EA (1) EA201892446A1 (enExample)
ES (1) ES2977545T3 (enExample)
GB (1) GB201608323D0 (enExample)
IL (1) IL262654A (enExample)
MX (1) MX2018013215A (enExample)
SG (1) SG11201809229VA (enExample)
WO (1) WO2017194646A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CA3094934A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CN115484931A (zh) * 2020-03-11 2022-12-16 西莱克塔生物科技公司 与合成纳米载体相关的方法和组合物
EP4173637A4 (en) * 2020-06-29 2024-08-07 Hanall Biopharma Co., Ltd. FORMULATION FOR ANTI-FCRN ANTIBODIES
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
WO2023099607A1 (en) 2021-12-01 2023-06-08 UCB Biopharma SRL Formulations comprising fab-peg
CN119233815A (zh) * 2022-05-20 2024-12-31 株式会社大赛璐 液态医药组合物
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
CN115708810A (zh) * 2022-11-03 2023-02-24 浙江新码生物医药有限公司 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途
CN120882751A (zh) * 2023-03-08 2025-10-31 依牧诺万科学有限公司 含聚山梨酯赋形剂的高浓度蛋白质制剂及其制备方法
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
WO2014019727A1 (en) 2012-05-14 2014-02-06 Ucb Pharma S.A. Anti-fcrn antibodies
JP2014516953A (ja) 2011-05-10 2014-07-17 アムジエン・インコーポレーテツド コレステロール関連障害を治療または予防する方法
JP2015514090A (ja) 2012-03-26 2015-05-18 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
BRPI0711608B8 (pt) * 2006-05-12 2021-05-25 Bharat Biotech Int Ltd composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US8788028B2 (en) 2010-07-28 2014-07-22 Medtronic, Inc. Parasympathetic stimulation to enhance tachyarrhythmia detection
EP2648750B1 (en) 2010-12-10 2017-01-25 Novartis AG Antibody formulation
US9220776B2 (en) * 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014093206A1 (en) 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Lyophilized spherical pellets of anti-il-23 antibodies
TW201542226A (zh) * 2014-02-12 2015-11-16 Sanofi Sa 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
AU2015332151A1 (en) 2014-10-18 2017-04-27 Pfizer Inc. Anti-IL-7R antibody compositions
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
JP2014516953A (ja) 2011-05-10 2014-07-17 アムジエン・インコーポレーテツド コレステロール関連障害を治療または予防する方法
JP2015514090A (ja) 2012-03-26 2015-05-18 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
WO2014019727A1 (en) 2012-05-14 2014-02-06 Ucb Pharma S.A. Anti-fcrn antibodies

Also Published As

Publication number Publication date
IL262654A (en) 2018-12-31
EP3454899C0 (en) 2024-03-20
KR102436694B1 (ko) 2022-08-25
AU2017264553A1 (en) 2018-12-13
CN109069643A (zh) 2018-12-21
AR108449A1 (es) 2018-08-22
RU2018141591A3 (enExample) 2021-01-13
CA3022124A1 (en) 2017-11-16
EA201892446A1 (ru) 2019-04-30
CL2018003178A1 (es) 2019-02-01
KR20190008320A (ko) 2019-01-23
US20200048346A1 (en) 2020-02-13
RU2018141591A (ru) 2020-06-15
US11407835B2 (en) 2022-08-09
ES2977545T3 (es) 2024-08-26
MX2018013215A (es) 2019-02-21
JP2019514998A (ja) 2019-06-06
EP3454899A1 (en) 2019-03-20
EP3454899B1 (en) 2024-03-20
WO2017194646A1 (en) 2017-11-16
CO2018011733A2 (es) 2019-02-08
SG11201809229VA (en) 2018-11-29
BR112018072264A2 (pt) 2019-02-12
GB201608323D0 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
JP7126454B2 (ja) 医薬組成物
JP6769879B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
TW201347791A (zh) 抗體調配物
JP6346189B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
CN107249571B (zh) 药物制剂
JP6339578B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
US20200390705A1 (en) Method for reducing the reconstitution time of spray-dried protein formulations
RU2775944C2 (ru) Фармацевтическая композиция
EA041921B1 (ru) Фармацевтическая композиция

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220816

R150 Certificate of patent or registration of utility model

Ref document number: 7126454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250